Cargando…

Lyotropic Liquid Crystalline Nanostructures as Drug Delivery Systems and Vaccine Platforms

Lyotropic liquid crystals result from the self-assembly process of amphiphilic molecules, such as lipids, into water, being organized in different mesophases. The non-lamellar formed mesophases, such as bicontinuous cubic (cubosomes) and inverse hexagonal (hexosomes), attract great scientific intere...

Descripción completa

Detalles Bibliográficos
Autores principales: Chountoulesi, Maria, Pispas, Stergios, Tseti, Ioulia K., Demetzos, Costas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9028109/
https://www.ncbi.nlm.nih.gov/pubmed/35455426
http://dx.doi.org/10.3390/ph15040429
_version_ 1784691534747140096
author Chountoulesi, Maria
Pispas, Stergios
Tseti, Ioulia K.
Demetzos, Costas
author_facet Chountoulesi, Maria
Pispas, Stergios
Tseti, Ioulia K.
Demetzos, Costas
author_sort Chountoulesi, Maria
collection PubMed
description Lyotropic liquid crystals result from the self-assembly process of amphiphilic molecules, such as lipids, into water, being organized in different mesophases. The non-lamellar formed mesophases, such as bicontinuous cubic (cubosomes) and inverse hexagonal (hexosomes), attract great scientific interest in the field of pharmaceutical nanotechnology. In the present review, an overview of the engineering and characterization of non-lamellar lyotropic liquid crystalline nanosystems (LLCN) is provided, focusing on their advantages as drug delivery nanocarriers and innovative vaccine platforms. It is described that non-lamellar LLCN can be utilized as drug delivery nanosystems, as well as for protein, peptide, and nucleic acid delivery. They exhibit major advantages, including stimuli-responsive properties for the “on demand” drug release delivery and the ability for controlled release by manipulating their internal conformation properties and their administration by different routes. Moreover, non-lamellar LLCN exhibit unique adjuvant properties to activate the immune system, being ideal for the development of novel vaccines. This review outlines the recent advances in lipid-based liquid crystalline technology and highlights the unique features of such systems, with a hopeful scope to contribute to the rational design of future nanosystems.
format Online
Article
Text
id pubmed-9028109
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-90281092022-04-23 Lyotropic Liquid Crystalline Nanostructures as Drug Delivery Systems and Vaccine Platforms Chountoulesi, Maria Pispas, Stergios Tseti, Ioulia K. Demetzos, Costas Pharmaceuticals (Basel) Review Lyotropic liquid crystals result from the self-assembly process of amphiphilic molecules, such as lipids, into water, being organized in different mesophases. The non-lamellar formed mesophases, such as bicontinuous cubic (cubosomes) and inverse hexagonal (hexosomes), attract great scientific interest in the field of pharmaceutical nanotechnology. In the present review, an overview of the engineering and characterization of non-lamellar lyotropic liquid crystalline nanosystems (LLCN) is provided, focusing on their advantages as drug delivery nanocarriers and innovative vaccine platforms. It is described that non-lamellar LLCN can be utilized as drug delivery nanosystems, as well as for protein, peptide, and nucleic acid delivery. They exhibit major advantages, including stimuli-responsive properties for the “on demand” drug release delivery and the ability for controlled release by manipulating their internal conformation properties and their administration by different routes. Moreover, non-lamellar LLCN exhibit unique adjuvant properties to activate the immune system, being ideal for the development of novel vaccines. This review outlines the recent advances in lipid-based liquid crystalline technology and highlights the unique features of such systems, with a hopeful scope to contribute to the rational design of future nanosystems. MDPI 2022-03-31 /pmc/articles/PMC9028109/ /pubmed/35455426 http://dx.doi.org/10.3390/ph15040429 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Chountoulesi, Maria
Pispas, Stergios
Tseti, Ioulia K.
Demetzos, Costas
Lyotropic Liquid Crystalline Nanostructures as Drug Delivery Systems and Vaccine Platforms
title Lyotropic Liquid Crystalline Nanostructures as Drug Delivery Systems and Vaccine Platforms
title_full Lyotropic Liquid Crystalline Nanostructures as Drug Delivery Systems and Vaccine Platforms
title_fullStr Lyotropic Liquid Crystalline Nanostructures as Drug Delivery Systems and Vaccine Platforms
title_full_unstemmed Lyotropic Liquid Crystalline Nanostructures as Drug Delivery Systems and Vaccine Platforms
title_short Lyotropic Liquid Crystalline Nanostructures as Drug Delivery Systems and Vaccine Platforms
title_sort lyotropic liquid crystalline nanostructures as drug delivery systems and vaccine platforms
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9028109/
https://www.ncbi.nlm.nih.gov/pubmed/35455426
http://dx.doi.org/10.3390/ph15040429
work_keys_str_mv AT chountoulesimaria lyotropicliquidcrystallinenanostructuresasdrugdeliverysystemsandvaccineplatforms
AT pispasstergios lyotropicliquidcrystallinenanostructuresasdrugdeliverysystemsandvaccineplatforms
AT tsetiiouliak lyotropicliquidcrystallinenanostructuresasdrugdeliverysystemsandvaccineplatforms
AT demetzoscostas lyotropicliquidcrystallinenanostructuresasdrugdeliverysystemsandvaccineplatforms